Sponsored – Est. Read 9 Min
Promising New Therapies for Mental Health Treatment Offer High-Upside Opportunities in a Potential $538 Billion Market
With its unique business model – and a clear path to profitability – Numinus Wellness Inc. (TO: NUMI); (OTCQX: NUMIF) offers investors smart exposure to the rapidly growing mental health market.
Discover why Numinus Wellness now stands alone at the forefront of the behavioral health revolution.
Download the Corporate Presentation
Download the Corporate Presentation
Learn more about Numinus Wellness Inc. by gaining access to the company’s latest corporate presentation
Without question, we are right now in the midst of a massive global mental health epidemic.
Across the globe, rates for mental illness, addiction and trauma are skyrocketing…with no sign of slowing down.
- One in four Canadians 18+ screened positive for symptoms of depression, anxiety or PTSD in spring 2021, up from one in five the previous fall[i].
- During the pandemic, roughly 4 in 10 adults in the U.S. reported symptoms of anxiety or depressive disorder, up from 1 in 10 in the first half of 2019[ii].
- And 40.3 million Americans aged 12+ had a substance use disorder in 2020[iii].
The World Health Organization estimates that the cost to the global economy of the two most common mental health conditions – depression and anxiety – at $1 trillion[iv].
Meeting this extraordinary challenge presented by our mental health crisis has become one of the world’s most urgent priorities.
Fortunately, psychedelic medicines have been shown, in many cases, to have a significant impact in helping patients dealing with mental health issues.
In fact, MDMA-assisted therapy for PTSD shows substantial clinical impact and potential annual savings of millions of dollars.[v]
we are right now in the midst of a massive global mental health epidemic.
Across the globe, rates for mental illness.
Two different Phase 3 trials indicated a significant improvement of PTSD symptoms in patients who received a course of MDMA-assisted therapy.
As these new treatments are now emerging, one company at the forefront of helping develop and implement these psychedelic-based treatment solutions is Numinus Wellness Inc. (TO: NUMI); (OTCQX: NUMIF).
Numinus is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy.
The company is uniquely positioned as a leading provider of clinical infrastructure as novel drugs and therapeutic protocols near regulatory approval.
7 Reasons Why You Should Strongly Consider the Potential Upside for Numinus Wellness Inc. Today
- Helping Provide Much-Needed Solutions for a Massive Global Crisis. Numinus is working to help the psychedelics sector deliver effective treatments to the millions of individuals currently suffering from mental health conditions worldwide.
- Serving High Growth Niche in a Global Health Market Projected to Grow to $538 Billion by 2030. The global mental health market is set to grow from $380 billion in 2020 to $538 billion by 2030[i]. Numinus is developing and implementing solutions designed to best serve this rapidly-growing market.
- Uniquely Positioned to Benefit from Multiple Drivers of Industry Growth. Thanks to its unique business model, Numinus is not reliant on any development of any specific drug for its revenue growth. The company is instead smartly positioned to partner with drug developers to provide patient access to psychedelic-based therapies.
- Numinus is the Industry’s Leading Provider of Clinical Infrastructure. This clinical infrastructure is critical to the future of the psychedelics sector as novel drugs and therapeutic drugs near regulatory approval. With 9 wellness clinics in Canada and the U.S., as well as a robust practitioner training program in place, Numinus is establishing a leadership position in the mental health care revolution.
- Significant Potential Near-Term Catalyst with New Therapy. The FDA’s recent acceptance of a new MDMA-based drug application from Lykos Therapeutics (formerly MAPS) is a significant potential catalyst for Numinus Wellness. Should Lykos receive FDA approval for this first-of-its-kind MDMA-assisted therapy for treatment of PTSD, Numinus stands poised to help support their efforts by delivering therapy via the company’s wellness clinics and its practitioner training program.
- Numinus is a Preferred Psychedelic Drug Development Partner for drug developers, non-profits and academic institutions. Some of Numinus Wellness’ partners include MindMed, Merck, Alto Neuroscience, MAPS and the University of Utah.
- Numinus is a Revenue Generating Company with a Clear Path to Profitability. Thanks to its wellness clinics and practitioner training, the company already has a consistent revenue stream and a path to profitability. This fact, combined with the blue sky potential of its drug development research, provides investors with a unique high-upside opportunity.
Numinus Wellness Inc.’s Unique Business Model Provides Short-Term Revenue…Significant Blue Sky Potential…and a Clear Path to Profitability
Numinus Wellness Inc. (TO: NUMI); (OTCQX: NUMIF) offers a rare opportunity for investors as the psychedelic treatment market evolves for one simple reason:
Its unique business model.
To date, most of the investment in the psychedelic space has been in the area of drug development. And there’s no question that drug development can be lucrative.
Many investors have been attracted to the high upside associated with a potential “home run” in drug development.
But the reality is…it generally takes a long time – as much as ten years from start to finish – for approvals. And as companies are discovering, drug development is only one part of the mental health treatment picture.
In order to deliver effective treatment, there’s another key component:
Therapy with a trained psychotherapist is a crucial factor in treatment of most mental health conditions.
And that happens to be an area where Numinus Wellness has emerged as a clear leader.
Numinus Wellness currently operates 9 wellness clinics across the U.S. and Canada offering a wide-range of mental health treatments, including traditional talk therapy, Ketamine-assisted therapy, and transcranial magnetic stimulation.
The company’s corporately-owned clinic locations are often located in clusters, which allow Numinus to efficiently operate and generate regional brand awareness.
And the company’s new Numinus Network platform offers licensing and partnership opportunities to third-party clinic operators and practitioners.
Numinus Offers True Industry-Wide Potential as It is Not Dependent on the Success of Any Single Drug Developer
Numinus Wellness has employed a business model that not only aims for the high potential upside associated with drug development, but also focuses on providing treatment sites and clinical infrastructure to offer therapy.
This means that Numinus Wellness is not beholden to the success of its own drug development – or any individual drug development partner.
Instead, the company is uniquely positioned to benefit from any and all drugs that may get approved in the psychedelic space.
With treatment rooms specifically designed for anticipated psychedelic-assisted therapy (PAT) protocols, experienced practitioners to provide the treatments, training opportunities to grow the number of PAT-certified practitioners, and insurance payer expertise, Numinus Wellness is in an ideal position to provide the necessary clinical infrastructure to the psychedelics sector.
In fact, this unique positioning is right now playing out in a significant way…and that’s what makes this opportunity so attractive – and time-sensitive – to individual investors.
Here’s what is now unfolding:
FDA Acceptance of New Drug Application from Lykos Therapeutics (formerly MAPS) is a Significant Potential Catalyst for Numinus Wellness
In February 2024, the U.S. Food and Drug Administration accepted a new drug application for a submission by Lykos Therapeutics (formerly MAPS).
This submission was for a new drug application for MDMA-assisted therapy to be used in combination with psychological intervention for individuals with PTSD.
The FDA has granted the application a priority review, which mandates the authority to take action within six months. A Prescription Drug User Fee Act target action date of August 11, 2024 has been set.
This is massive news for the industry, as if approved, this would be the first MDMA-assisted therapy available in the United States for millions of Americans struggling with PTSD.
Numinus Wellness Inc.’s Cedar Clinical Research facilities was a proud collaboration partner with Lykos (formerly MAPS) in the clinical research for this application.
But what happens next could be a significant potential catalyst for Numinus Wellness Inc. (TO: NUMI); (OTCQX: NUMIF).
In anticipation of Lykos Therapeutics receiving FDA approval for this treatment, there needs to be a dedicated focus on building the infrastructure to administer this new treatment if the FDA approves it.
That’s because psychotherapy is a key component of the proposed treatment…and Lykos could soon need a large number of sites that are capable of providing this therapy.
Numinus Wellness is the only multi-site wellness clinic providers that is capable of helping provide these services that are required as part of the treatment.
In fact, Numinus was at the clinical trial sites during drug development and has run the protocol that will be required for delivery of treatment.
The Only Game in Town: How Numinus Wellness
is Positioned Perfectly to Help
Administer MDMA-Assisted Therapy
Think about it: Should this new drug from Lykos Therapeutics receive FDA approval – and a target action date of August 11, 2024 has been set – there is likely to be a significant amount of initial interest and demand for the new treatment.
And Numinus Wellness is positioned as a potential Only-Game-in-Town for the clinical component of this new treatment.
Already in its Canadian clinics, Numinus is currently treating patients with MDMA-assisted therapy on a limited scope under the current regulatory exceptions.
The combination of Numinus Wellness Inc.’s experience and infrastructure positions the company to be a leading provider of psychedelic-assisted therapy at this critical juncture.
You should also consider this:
The single largest potential bottleneck for Lykos Therapeutics in administering treatment following FDA approval would be identifying practitioners trained to offer the associated therapy.
Numinus Wellness has built out an entire training program designed to help get practitioners properly trained as quickly as possible.
As a matter of fact, it’s a training program that provides Numinus Wellness with an impressive 75% profit margin. So let’s do some quick math:
Lykos estimates that they will need to get a minimum of 30,000 practitioners trained over the next three years as part of this program.
That training costs roughly $9,000 per practitioner…so that could mean as much as $270 million in revenue at a profit margin of 75% ($202.5 million.)
Obviously that type of potential revenue would be significant for Numinus Wellness Inc. (TO: NUMI); (OTCQX: NUMIF), which currently has a market cap of just over US $24 million.
Another factor to keep in mind as it relates to the potential for Numinus Wellness and the administration of the clinical component of this new treatment – pending FDA approval – is this:
Rick Doblin, Ph.D., the Founder and President of MAPS – the former parent of Lykos Therapeutics – has recently joined Numinus Wellness as an unpaid, non-exclusive strategic adviser to help guide enhancements to and foster empirical validation of Numinus treatment modalities and training assets related to MDMA-assisted therapy.
Numinus and Dr. Doblin share a common goal of ensuring broad access to treatment, focusing on inclusivity and making quality care accessible to all those seeking transformative therapeutic treatments.
This appointment fortifies Numinus Wellness Inc.’s commitment to training programs which support the efficacy and safety of MDMA-assisted therapy for PTSD.
Impressive Blue Sky Potential: Numinus Wellness is a Preferred Drug Development Partner for a Growing Number of Organizations
In the area of clinical research and drug development, Numinus also offers significant upside potential.
The company’s Cedar Clinical Research (CCR) provides contract research site management services specializing in psychedelic medicine to third-party drug development companies.
CCR works with many of the psychedelics sector’s leading companies, and also runs clinical trial research sites for traditional drug developers.
Its research capabilities include phase I-IV clinical trials focused on psychedelics and mental health. And CCR specializes in clinical trial design, patient recruitment, screening and enrollment, and patient management and data collection.
A Proven, Experienced Management Team is Expertly Guiding Numinus into a Leadership Position Within its Industry
Numinus Wellness Inc. is led by scientific, medical and business leaders whose expertise spans international healthcare research, policy reform, regulatory affairs, capital markets, technology and government relations.
This impressive team includes:
Peyton Nyquvest – Founder & CEO
Payton has a deep understanding of the psychedelic industry from its infancy, driven by life-saving personal experiences with multiple therapy modalities. Additionally, Payton has deep business leadership experience, particularly in the finance sector, and is a recognized innovator and visionary in mental health care. He is responsible for raising more than $70 million for Numinus and brings more than 15 years of experience working in finance, investment and retail banking.
Michael Tan, MBA – President & Chief Operating Officer
A transformative leader excelling at strategically integrating operations, medical, and therapy services. His executive expertise in business transformation, demonstrated at tier-one retailers such as Saks Fifth Avenue and Hudson’s Bay, and as the inaugural leader of BC’s cannabis operations, has been pivotal to Numinus’ growth. Michael’s leadership, enriched through personal experience with various therapeutic approaches, drives innovative and sustainable approaches in mental health care.
Nikhil Handa – Chief Financial Officer
Nikhil has led finance and corporate development initiatives for companies across a wide variety of sectors. Most recently, he was CFO at The Supreme Cannabis Company, Inc., where he was responsible for executing the sale of the company to Canopy Growth in 2021. Prior to this, he was the VP of Finance at Well.ca, a leading online destination for health, held operational roles at Restaurant Brands International, and held roles in the mergers and acquisition group of RBC Capital Markets.
Dr. Reid Robison, MD, MBA – Chief Clinical Officer
Psychiatry leader and co-founder of Cedar Psychiatry. Recognized for leading research and treatment of eating disorders (EDs), early adoption of ketamine in psychiatry, and social entrepreneurship. Previously coordinating investigator in a MAPS-sponsored study on MDMA for EDs and lead of a Janssen study on ketamine for treatment-resistant depression. Dr. Robison was previously Chief Medical Officer at Novamind.
Dr. Paul Thielking, MD – Chief Science Officer
Certified psychiatry, hospice/palliative medicine, and integrative medicine leader and trained in psychedelic therapy (CIIS). Extensive experience developing interventions for people with serious illness and substance use disorders, including psilocybin for depression in cancer patients, ketamine for opioid use, and tobacco treatment. Dr. Thielking was previously Chief Scientific Officer at Novamind.
7 Reasons Why You Should Strongly Consider the Potential Upside for Numinus Wellness Inc. Today
- Helping Provide Much-Needed Solutions for a Massive Global Crisis. Numinus is working to help the psychedelics sector deliver effective treatments to the millions of individuals currently suffering from mental health conditions worldwide.
- Serving High Growth Niche in a Global Health Market Projected to Grow to $538 Billion by 2030. The global mental health market is set to grow from $380 billion in 2020 to $538 billion by 2030[i]. Numinus is developing and implementing solutions designed to best serve this rapidly-growing market.
- Uniquely Positioned to Benefit from Multiple Drivers of Industry Growth. Thanks to its unique business model, Numinus is not reliant on any development of any specific drug for its revenue growth. The company is instead smartly positioned to partner with drug developers to provide patient access to psychedelic-based therapies.
- Numinus is the Industry’s Leading Provider of Clinical Infrastructure. This clinical infrastructure is critical to the future of the psychedelics sector as novel drugs and therapeutic drugs near regulatory approval. With 9 wellness clinics in Canada and the U.S., as well as a robust practitioner training program in place, Numinus is establishing a leadership position in the mental health care revolution.
- Significant Potential Near-Term Catalyst with New Therapy. The FDA’s recent acceptance of a new MDMA-based drug application from Lykos Therapeutics (formerly MAPS) is a significant potential catalyst for Numinus Wellness. Should Lykos receive FDA approval for this first-of-its-kind MDMA-assisted therapy for treatment of PTSD, Numinus stands poised to help support their efforts by delivering therapy via the company’s wellness clinics and its practitioner training program.
- Numinus is a Preferred Psychedelic Drug Development Partner for drug developers, non-profits and academic institutions. Some of Numinus Wellness’ partners include MindMed, Merck, Alto Neuroscience, MAPS and the University of Utah.
- Numinus is a Revenue Generating Company with a Clear Path to Profitability. Thanks to its wellness clinics and practitioner training, the company already has a consistent revenue stream and a path to profitability. This fact, combined with the blue sky potential of its drug development research, provides investors with a unique high-upside opportunity.
Begin Your Research Now
Learn more about Numinus Wellness Inc. by gaining access to the company’s latest corporate presentation
[i] https://www.cnn.com/2022/10/05/health/cnn-kff-mental-health-poll-wellness/index.html
[ii] https://www150.statcan.gc.ca/n1/daily-
quotidien/210927/dq210927a-eng.htm
[iii] https://www.kff.org/coronavirus-covid-19/issue-
brief/the-implications-of-covid-19-for-mental-health-and-substance-use/
[iv] https://wwwnc.cdc.gov/travel/yellowbook/2024/additional-
considerations/substance-use#:~:
text=CDC%20Yellow%20Book%202024,-
Travelers%20with%20Additional&text=
In%202020%2C%2040.3%
20million%20people,SUD)%20in%20the%20past%20year.
[v] https://www.who.int/teams/mental-health-and-substance-use/promotion-
prevention/mental-health-in-the-workplace
[vi] https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239997
[vii] https://www.globenewswire.com/news-release/2021/07/13/2261999/0/en/Global-Mental-
Health-Market-To-Garner-537-97-Million-By-2030-Allied-Market-Research.html
[viii] https://www.militarytimes.com/news/your-military/2024/02/13/psychedelic-to-receive-fast-
track-review-as-possible-ptsd-drug/
[ix] https://thehill.com/homenews/4465253-lawmakers-advocates-
champion-mdma-as-a-game-changer-in-ptsd-treatment/
[x] https://www.globenewswire.com/news-release/2021/07/13/2261999/0/en/Global
-Mental-Health-Market-To-Garner-537-97-Million-By-2030
Disclaimer: